טוען...
Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies
In recent years, new classes of molecules have been established as opportunities for the treatment of breast cancer. The approval of trastuzumab, the antibody against Her2/neu, in the late 1990s was followed by the approval of the antiangiogenic antibody bevacizumab in 2007. Progress in the understa...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
S. Karger GmbH
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2942015/ https://ncbi.nlm.nih.gov/pubmed/21160542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000190063 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|